DiagnaMed Begins Test Launch of CERVAI
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
A test launch is currently underway for CERVAI, which has been deemed as a world-first consumer brain health and wellness AI solution. The test is being conducted by the University of Miami’s Comprehensive Center for Brain Health.
“We are creating momentum for the upcoming commercial launch of CERVAI, a world-first consumer brain health and wellness solution that estimates brain age and provides a brain health score, and being tested at a reputable University brain health center serves as a validation of CERVAI™’s potential in providing a unique service to clinics seeking a solution that helps bridge the gaps in physical and cognitive health while enhancing client engagement and design personalized interventions in improving overall brain health,” commented Fabio Chianelli, CEO of DiagnaMed Holdings.
The launch marks a significant milestone for DiagnaMed Holdings (CSE: DMED), whom has been developing the solution hand in hand with that of the University of Miami’s Miller School of Medicine. CERVAI has been developed to assess risk levels for the development of Alzheimer’s and other neurological issues through the use of a series of tests.
These tests produce three results, referred to as a Resilience Index, a Vulnerability Index, and a Number-Symbol Coding Task. When brought together, these results assist in assessing a patients risk for developing neurological issues by providing a snapshot of brain health.
A cross-sectional study previously conducted by the University that tested 230 participants identified that the methodology used by CERVAI demonstrated that individuals with abnormal test scores were 95.7% likely to be impaired, with a misclassification rate of 9.7%. The methodology is said to have outperformed the Montreal Cognitive Assessment, an industry standard in the area of early detection of mild cognitive impairments that has been in use since 2000.
Initial testing of CERVAI will focus on evaluating the brain health assessment portion of the tool.
A test pilot program meanwhile is open at 25 clinics across Canada and the US.
DiagnaMed Holdings last traded at $0.03 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
